Sub-optimal serum gentamicin concentrations in sickle cell disease patients utilizing the Hartford protocol

Ahmed A. Abusham, A. H. Mohammed, S. S. Alkindi, M. M. Hassan, I. S. Al-Zakwani

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

What is known and Objectives: Several studies have reported that use of the Hartford nomogram in different patients' population was associated with low serum gentamicin concentrations (SGC) at different intervals or midpoints. This study was intended to determine the prevalence and predictors of SGC in patients with sickle cell disease (SCD) as another population representing low SGC while utilizing the Hartford protocol. Methods: This retrospective observational study was carried out in a University-teaching hospital in Oman. The study was conducted from January 2005 through May 2008 and included all adult patients with SCD admitted during that time. Fourhundred and seven SGC representing 248 SCD patients were evaluated. The serum gentamicin concentration was considered sub-optimal if it was 23 years of age (95% CI: 1·14-3·45; P = 0·015). Patients with creatinine clearance of ≥200 mL/min were 5Æ20 times more likely to have sub-optimal SGC compared with those with creatinine clearance

Original languageEnglish
Pages (from-to)212-216
Number of pages5
JournalJournal of Clinical Pharmacy and Therapeutics
Volume37
Issue number2
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Sickle Cell Anemia
Gentamicins
Serum
Creatinine
Oman
Nomograms
Teaching Hospitals
Population
Observational Studies
Retrospective Studies

Keywords

  • Gentamicin extended interval dosing
  • Hartford nomogram
  • Oman
  • Sickle cell disease

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Sub-optimal serum gentamicin concentrations in sickle cell disease patients utilizing the Hartford protocol. / Abusham, Ahmed A.; Mohammed, A. H.; Alkindi, S. S.; Hassan, M. M.; Al-Zakwani, I. S.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 37, No. 2, 04.2012, p. 212-216.

Research output: Contribution to journalArticle

@article{bcbdc720ca2b41bf86580b5acbc91e04,
title = "Sub-optimal serum gentamicin concentrations in sickle cell disease patients utilizing the Hartford protocol",
abstract = "What is known and Objectives: Several studies have reported that use of the Hartford nomogram in different patients' population was associated with low serum gentamicin concentrations (SGC) at different intervals or midpoints. This study was intended to determine the prevalence and predictors of SGC in patients with sickle cell disease (SCD) as another population representing low SGC while utilizing the Hartford protocol. Methods: This retrospective observational study was carried out in a University-teaching hospital in Oman. The study was conducted from January 2005 through May 2008 and included all adult patients with SCD admitted during that time. Fourhundred and seven SGC representing 248 SCD patients were evaluated. The serum gentamicin concentration was considered sub-optimal if it was 23 years of age (95{\%} CI: 1·14-3·45; P = 0·015). Patients with creatinine clearance of ≥200 mL/min were 5{\AE}20 times more likely to have sub-optimal SGC compared with those with creatinine clearance",
keywords = "Gentamicin extended interval dosing, Hartford nomogram, Oman, Sickle cell disease",
author = "Abusham, {Ahmed A.} and Mohammed, {A. H.} and Alkindi, {S. S.} and Hassan, {M. M.} and Al-Zakwani, {I. S.}",
year = "2012",
month = "4",
doi = "10.1111/j.1365-2710.2011.01261.x",
language = "English",
volume = "37",
pages = "212--216",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Sub-optimal serum gentamicin concentrations in sickle cell disease patients utilizing the Hartford protocol

AU - Abusham, Ahmed A.

AU - Mohammed, A. H.

AU - Alkindi, S. S.

AU - Hassan, M. M.

AU - Al-Zakwani, I. S.

PY - 2012/4

Y1 - 2012/4

N2 - What is known and Objectives: Several studies have reported that use of the Hartford nomogram in different patients' population was associated with low serum gentamicin concentrations (SGC) at different intervals or midpoints. This study was intended to determine the prevalence and predictors of SGC in patients with sickle cell disease (SCD) as another population representing low SGC while utilizing the Hartford protocol. Methods: This retrospective observational study was carried out in a University-teaching hospital in Oman. The study was conducted from January 2005 through May 2008 and included all adult patients with SCD admitted during that time. Fourhundred and seven SGC representing 248 SCD patients were evaluated. The serum gentamicin concentration was considered sub-optimal if it was 23 years of age (95% CI: 1·14-3·45; P = 0·015). Patients with creatinine clearance of ≥200 mL/min were 5Æ20 times more likely to have sub-optimal SGC compared with those with creatinine clearance

AB - What is known and Objectives: Several studies have reported that use of the Hartford nomogram in different patients' population was associated with low serum gentamicin concentrations (SGC) at different intervals or midpoints. This study was intended to determine the prevalence and predictors of SGC in patients with sickle cell disease (SCD) as another population representing low SGC while utilizing the Hartford protocol. Methods: This retrospective observational study was carried out in a University-teaching hospital in Oman. The study was conducted from January 2005 through May 2008 and included all adult patients with SCD admitted during that time. Fourhundred and seven SGC representing 248 SCD patients were evaluated. The serum gentamicin concentration was considered sub-optimal if it was 23 years of age (95% CI: 1·14-3·45; P = 0·015). Patients with creatinine clearance of ≥200 mL/min were 5Æ20 times more likely to have sub-optimal SGC compared with those with creatinine clearance

KW - Gentamicin extended interval dosing

KW - Hartford nomogram

KW - Oman

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84857966622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857966622&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2710.2011.01261.x

DO - 10.1111/j.1365-2710.2011.01261.x

M3 - Article

C2 - 21501204

AN - SCOPUS:84857966622

VL - 37

SP - 212

EP - 216

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 2

ER -